{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T18:54:45Z","timestamp":1784055285534,"version":"3.55.0"},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T00:00:00Z","timestamp":1484092800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0169845","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T14:07:09Z","timestamp":1484143629000},"page":"e0169845","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":58,"title":["Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis"],"prefix":"10.1371","volume":"12","author":[{"given":"Yu","family":"Nishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8808-5672","authenticated-orcid":true,"given":"Shuhei","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Yukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Nagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Taira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Kamata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Tanigawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Shiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tominaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,1,11]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1053\/j.gastro.2004.02.071","article-title":"Medical therapy for ulcerative colitis 2004","volume":"126","author":"SB Hanauer","year":"2004","journal-title":"Gastroenterology"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/gast.2001.26279","article-title":"The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study","volume":"121","author":"WA Faubion Jr.","year":"2001","journal-title":"Gastroenterology"},{"issue":"7","key":"ref3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1365-2036.2010.04234.x","article-title":"Systematic review: the costs of ulcerative colitis in Western countries","volume":"31","author":"RD Cohen","year":"2010","journal-title":"Alimentary pharmacology & therapeutics"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1053\/j.gastro.2005.03.003","article-title":"Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study","volume":"128","author":"G Jarnerot","year":"2005","journal-title":"Gastroenterology"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.autrev.2013.06.002","article-title":"Optimizing anti-TNF treatments in inflammatory bowel disease","volume":"13","author":"S Ben-Horin","year":"2014","journal-title":"Autoimmunity reviews"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/ecco-jcc\/jjv061","article-title":"Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease","volume":"9","author":"X Roblin","year":"2015","journal-title":"Journal of Crohn's & colitis"},{"issue":"8","key":"ref7","first-page":"3291","article-title":"A high preoperative neutrophil-to-lymphocyte ratio is associated with poor survival in patients with colorectal cancer","volume":"33","author":"M Shibutani","year":"2013","journal-title":"Anticancer research"},{"issue":"12","key":"ref8","first-page":"5567","article-title":"Prognostic value of preoperative inflammation-based prognostic scores in patients with stage IV colorectal cancer who undergo palliative resection of asymptomatic primary tumors","volume":"33","author":"K Maeda","year":"2013","journal-title":"Anticancer research"},{"issue":"3","key":"ref9","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s10120-010-0554-3","article-title":"High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer","volume":"13","author":"H Shimada","year":"2010","journal-title":"Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/cam4.204","article-title":"Neutrophil-to-lymphocyte ratio for predicting palliative chemotherapy outcomes in advanced pancreatic cancer patients","volume":"3","author":"P Xue","year":"2014","journal-title":"Cancer medicine"},{"issue":"3","key":"ref11","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s11912-002-0023-1","article-title":"The role of C-reactive protein as a prognostic indicator in advanced cancer","volume":"4","author":"FA Mahmoud","year":"2002","journal-title":"Current oncology reports"},{"issue":"7","key":"ref12","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/jgh.13287","article-title":"Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection","volume":"31","author":"K Tajiri","year":"2016","journal-title":"Journal of gastroenterology and hepatology"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"e0163397","DOI":"10.1371\/journal.pone.0163397","article-title":"Pretreatment Neutrophil to Lymphocyte Ratio Is Associated with Poor Survival in Patients with Stage I-III Non-Small Cell Lung Cancer","volume":"11","author":"J Wang","year":"2016","journal-title":"PloS one"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"e0153981","DOI":"10.1371\/journal.pone.0153981","article-title":"Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Localized and Advanced Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"11","author":"L Tang","year":"2016","journal-title":"PloS one"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4081\/reumatismo.2015.838","article-title":"Neutrophil-lymphocyte ratio, pain perception, and disease activity score may serve as important predictive markers for sustained remission in rheumatoid arthritis","volume":"67","author":"S Chandrashekara","year":"2015","journal-title":"Reumatismo"},{"issue":"6","key":"ref16","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.amjcard.2010.10.067","article-title":"Value of early risk stratification using hemoglobin level and neutrophil-to-lymphocyte ratio in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"107","author":"KH Cho","year":"2011","journal-title":"The American journal of cardiology"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.amjcard.2007.11.004","article-title":"Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction","volume":"101","author":"J Nunez","year":"2008","journal-title":"The American journal of cardiology"},{"issue":"5","key":"ref18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1136\/hrt.2009.174912","article-title":"Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies","volume":"96","author":"LP He","year":"2010","journal-title":"Heart (British Cardiac Society)"},{"issue":"8","key":"ref19","doi-asserted-by":"crossref","first-page":"e0161530","DOI":"10.1371\/journal.pone.0161530","article-title":"Prognostic Utility of Neutrophil-to-Lymphocyte Ratio on Adverse Clinical Outcomes in Patients with Severe Calcific Aortic Stenosis","volume":"11","author":"KI Cho","year":"2016","journal-title":"PloS one"},{"issue":"7\u20138","key":"ref20","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s00508-014-0683-5","article-title":"Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis?","volume":"127","author":"E Posul","year":"2015","journal-title":"Wiener klinische Wochenschrift"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.kjms.2015.10.001","article-title":"The relationship between the neutrophil-lymphocyte ratio and disease activity in patients with ulcerative colitis","volume":"31","author":"AK Demir","year":"2015","journal-title":"The Kaohsiung journal of medical sciences"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.clinre.2012.06.004","article-title":"Assessment of neutrophil-lymphocyte ratio in ulcerative colitis: a promising marker in predicting disease severity","volume":"36","author":"S Torun","year":"2012","journal-title":"Clinics and research in hepatology and gastroenterology"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/jcla.21564","article-title":"Neutrophil-lymphocyte ratio as a predictor of disease severity in ulcerative colitis","volume":"27","author":"M Celikbilek","year":"2013","journal-title":"Journal of clinical laboratory analysis"},{"issue":"1","key":"ref24","first-page":"127","article-title":"Neutrophil-lymphocyte ratio in Crohn's disease patients predicts sustained response to infliximab 52-week therapy","volume":"24","author":"MK Wlodarczyk","year":"2015","journal-title":"Journal of gastrointestinal and liver diseases: JGLD"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1272\/jnms.83.118","article-title":"Neutrophil\/Lymphocyte Ratio in Patients with Rheumatoid Arthritis Treated with Biological Agents","volume":"83","author":"M Koiwa","year":"2016","journal-title":"Journal of Nippon Medical School = Nippon Ika Daigaku zasshi"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ibd.20520","article-title":"Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis","volume":"14","author":"JD Lewis","year":"2008","journal-title":"Inflammatory bowel diseases"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.crohns.2010.04.004","article-title":"Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects","volume":"4","author":"M Allez","year":"2010","journal-title":"Journal of Crohn's & colitis"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4291\/wjgp.v5.i3.293","article-title":"Predictors of response to anti-tumor necrosis factor therapy in ulcerative colitis","volume":"5","author":"E Zampeli","year":"2014","journal-title":"World journal of gastrointestinal pathophysiology"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/MIB.0b013e3182802909","article-title":"Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission","volume":"19","author":"A Armuzzi","year":"2013","journal-title":"Inflammatory bowel diseases"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/apt.12145","article-title":"One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2","volume":"37","author":"WJ Sandborn","year":"2013","journal-title":"Alimentary pharmacology & therapeutics"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev.immunol.23.021704.115653","article-title":"How neutrophils kill microbes","volume":"23","author":"AW Segal","year":"2005","journal-title":"Annual review of immunology"},{"issue":"3","key":"ref32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1042\/cs0690241","article-title":"The role of phagocytes in inflammatory bowel disease","volume":"69","author":"A Hermanowicz","year":"1985","journal-title":"Clinical science (London, England: 1979)"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/0090-1229(82)90201-X","article-title":"Inflammatory bowel disease: prevalence and level of activation of circulating T-lymphocyte subpopulations mediating suppressor\/cytotoxic and helper function as defined by monoclonal antibodies","volume":"25","author":"JK Roche","year":"1982","journal-title":"Clinical immunology and immunopathology"},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1744-9987.1998.tb00082.x","article-title":"Granulocyte apheresis in inflammatory bowel disease: possible mechanisms of effect","volume":"2","author":"BJ Rembacken","year":"1998","journal-title":"Therapeutic apheresis: official journal of the International Society for Apheresis and the Japanese Society for Apheresis"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/gut.25.1.32","article-title":"Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques","volume":"25","author":"WS Selby","year":"1984","journal-title":"Gut"},{"issue":"8","key":"ref36","first-page":"2553","article-title":"Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance","volume":"8","author":"TK Hoffmann","year":"2002","journal-title":"Clinical cancer research: an official journal of the American Association for Cancer Research"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/gut.2009.201533","article-title":"The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful","volume":"60","author":"S Ben-Horin","year":"2011","journal-title":"Gut"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/00365521.2010.536254","article-title":"Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease","volume":"46","author":"C Steenholdt","year":"2011","journal-title":"Scandinavian journal of gastroenterology"},{"issue":"5","key":"ref39","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"W Wang","year":"2008","journal-title":"Clinical pharmacology and therapeutics"},{"issue":"22","key":"ref40","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1182\/blood-2011-12-401133","article-title":"Endocytosis of soluble immune complexes leads to their clearance by FcgammaRIIIB but induces neutrophil extracellular traps via FcgammaRIIA in vivo","volume":"120","author":"K Chen","year":"2012","journal-title":"Blood"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0169845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T07:58:47Z","timestamp":1568707127000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0169845"}},"subtitle":[],"editor":[{"given":"Emiko","family":"Mizoguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,1,11]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,1,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0169845","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,11]]}}}